← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Precyte, Inc.
Potomac, MD
$7,580,161
Total funding
4
Grants
Funding over time
peak $2M · FY2015–21$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,580,161 · 4
By mechanism
R44$6,980,777 · 2
R43$599,384 · 2
Investigators at Precyte, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease$1,151,844
R44 · FY2015 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease$998,853
R44 · FY2019 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease$998,853
R44 · FY2020 · AG
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease$996,801
R44 · FY2018 · AG
Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer$996,232
R44 · FY2018 · CA
Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease$840,407
R44 · FY2016 · AG
Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer$509,200
R44 · FY2019 · CA
Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer$488,587
R44 · FY2021 · CA
Development of an Indicator Cell Assay for blood-based diagnosis of lung cancer$299,947
R43 · FY2016 · CA
Rational drug selection for Alzheimer's disease using Indicator Cell Assay Platform (iCAP)$299,437
R43 · FY2017 · AG